NMRA · Neumora Therapeutics, Inc.
$1.60
-0.13 (-7.51%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$300.63M
Shares
187.90M
Neumora Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Neumora Therapeutics, Inc. (NMRA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Conference
Investor event
2026-04-13
25th Annual Needham Virtual Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-30
Neumora Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
NMRA-215 obesity program and rat tox findings
NMRA-511 in Alzheimer's disease agitation
M4 PAM franchise / NMRA-898 in schizophrenia
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q2
2025-08-06
Neumora Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
Obesity / NMRA-215 NLRP3 inhibitor lead indication
M4 PAM franchise (NMRA-861, NMRA-898)
Navacaprant KOASTAL Phase III in MDD
Diluted EPS
$-0.33
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Neumora Therapeutics, Inc. Q1 FY2025 Earnings Call
Positive tone
KOASTAL Phase 3 program (navacaprant in MDD)
KOASTAL-1 failure and study modifications
NMRA-511 in Alzheimer's disease agitation
Diluted EPS
$-0.42
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Neumora Therapeutics, Inc. Q4 FY2024 Earnings Call
Positive tone
Navacaprant (KOASTAL Phase 3 program in MDD)
Regulatory engagement and trial design
Leadership transitions
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Neumora Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
Navacaprant / KOASTAL Phase 3 program in MDD
Pipeline breadth and additional programs
Clinical validation and safety profile
Diluted EPS
$-0.45
Audio
Transcript
Slides
8-K10-Q
Showing 1–6 of 6 earnings calls
Key facts
CIK
1885522
CUSIP
640979100
13F (30d)
114 filings
112 filers
Visit website
Investor relations